{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-26-000059","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2026-08-06T12:03:06+00:00","discovered_at":"2026-08-06T12:05:14.508599+00:00","generated_at":"2026-08-06T12:05:41.167526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q2 2026 revenue up 19% to $83.2M; net income $37.4M, EPS $0.28","bullets":["Total revenue $83.2M (+19% YoY); LUPKYNIS net product sales $79.4M (+19% YoY).","Net income $37.4M (+74% YoY); diluted EPS $0.28 (+75% YoY).","Cash from operations $52.5M; cash position $443.1M at June 30, 2026.","Reiterated 2026 total revenue guidance $315M-$325M (11-15% growth).","Initiated PRESERVE Phase 4 study combining LUPKYNIS with biologics; aritinercept in four indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-26-000059","json":"https://secwatch.observer/filing/0001600620-26-000059.json","markdown":"https://secwatch.observer/filing/0001600620-26-000059.md","text":"https://secwatch.observer/filing/0001600620-26-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/0001600620-26-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/auph-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:05:41.167526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}